Augurex Life Sciences Corp.

Home
Canada
Vancouver, BC
Augurex Life Sciences Corp.

Augurex is a clinical diagnostics leader advancing biomarker-driven solutions for the early detection and management of autoimmune diseases.

Augurex is a clinical diagnostics leader advancing biomarker-based tests for autoimmune diseases, enabling earlier, more precise detection and disease management to improve patient outcomes. Our lead products include JOINTstat® (14-3-3eta), which supports the diagnosis and monitoring of rheumatoid arthritis (RA), and SPINEstat™ (Anti-14-3-3eta Multiplex), a first-in-class blood test that aids in the diagnosis of axial spondyloarthritis (axSpA) and helps distinguish it from mechanical back pain. By enabling earlier, more precise diagnosis and better disease management, we empower clinicians and patients with the tools to take control of disease and improve long-term outcomes.

02/03/2026

February 2 marks Rheumatoid Arthritis (RA) Awareness Day, a time to recognize the millions of people around the world living with RA, a chronic autoimmune disease that affects far more than just the joints.

RA can bring daily pain, fatigue, and other challenges that are often invisible to others. With continued research, early diagnosis, and advances in treatment, we can help improve quality of life for everyone affected by RA.

At Augurex, we are proud to highlight our work in RA and our ongoing commitment to advancing diagnostic solutions that support rheumatologists and patients in improving outcomes and managing disease more effectively.

Let’s listen, support, and raise awareness. Because no one should have to navigate RA alone.

01/13/2026

We’re honored to be featured by Moira Gunn of NPR’s BioTech Nation as one of her Top 5 JPM interviews.

In this special JPM edition, Augurex was highlighted alongside four other companies shaping the future of biotech, with a focus on our work to reduce diagnostic delay in chronic back pain and axial spondyloarthritis, where patients often wait 7–10 years for the right diagnosis.

Thank you to Moira Gunn and BioTech Nation for the opportunity to share how Augurex is changing the diagnostic journey for patients who deserve answers sooner.

Listen to the interview here: https://podcasts.apple.com/us/podcast/youve-had-back-pain-for-7-10-years-neil-klompas-ceo-augurex/id876041079?i=1000744703417

12/03/2025

We’re proud to share that the Spondylitis Association of America (SAA) has featured Augurex’s research from the American College of Rheumatology (ACR) Convergence 2025 conference in a new article and in their recent eSUN newsletter.

Both pieces spotlight new findings on SPINEstat® (Anti-14-3-3eta Multiplex test) and its potential to improve early and accurate diagnosis of axial spondyloarthritis (axSpA), a chronic inflammatory condition that is often difficult to identify in its early stages.

Through their coverage, SAA continues to deliver trusted education to the spondyloarthritis community, including raising awareness of innovations that can shorten diagnostic delays and guide timely, personalized care.

SAA’s recognition underscores our commitment to ending diagnostic delays in axSpA and supporting patients and their physicians in achieving better outcomes.

🔗 Read the full article: https://spondylitis.org/research-new/new-research-highlights-promising-advances-in-axspa-diagnosis/

11/25/2025

We’re excited to share that Neil Klompas, Augurex CEO and President, joined the Progress, Potential, And Possibilities Podcast to discuss how tools like SPINEstat® can help improve early detection and referral accuracy in axial spondyloarthritis (axSpA).

In this episode, “Ending Diagnostic Delays in Autoimmune Conditions,” Neil highlights how SPINEstat® supports clinicians in distinguishing inflammatory axSpA from mechanical back pain, addressing a key contributor to the long diagnostic delay patients often experience.

🎧 Listen to the full episode:
https://www.progresspotentialpossibilities.com/podcast/episode/7961baa0/neil-klompas-ceo-augurex-ending-diagnostic-delays-in-autoimmune-conditions

11/24/2025

We are pleased to share that Dr. Norma Kor, Augurex Co-founder and Board Chair, was featured on the Spondylitis Association of America’s Spondycast Podcast.

In this episode, Dr. Biln discusses how new biomarkers, patient questionnaires, and tools like SPINEstat® (Anti-14-3-3eta Multiplex) can help close the long diagnostic delay in axial spondyloarthritis (axSpA) by improving early detection and referral accuracy, particularly in primary care settings.

🎧 Listen to the full episode: https://spondylitis.org/podcasts/episode-121-closing-the-diagnosis-delay-in-spondyloarthritis/

11/17/2025

We’re pleased to share that the 14-3-3eta test for rheumatoid arthritis (RA) will launch through Sonic Reference Laboratory in the United States on December 15, 2025.

This launch expands access to a blood test that enables earlier RA diagnostic and prognostic insights and more precise ongoing monitoring, giving patients and their healthcare providers a clearer view of disease progression and treatment response.

With Sonic Healthcare USA’s national reach and commitment to diagnostic excellence, this agreement represents another important step in Augurex’s deepening commitment in making advanced RA testing broadly accessible and improving outcomes for patients across the U.S. and around the world.

Read more in our press release: https://augurex.com/augurex-life-sciences-corp-announces-the-launch-of-the-14-3-3eta-test-for-rheumatoid-arthritis-diagnosis-and-monitoring-with-sonic-reference-laboratory/

11/02/2025

November 2–8 is National Pain Awareness Week, a time to recognize the millions of people living with chronic pain from conditions like rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).

At Augurex, we stand with patients and clinicians working toward earlier diagnosis and better management of inflammation-driven pain. Through innovative biomarker-based diagnostics such as JOINTstat® for RA and SPINEstat® for axSpA, we help enable earlier detection of disease activity to support timely treatment decisions before pain leads to lasting joint or spinal damage.

Together, we can raise awareness, improve understanding, and help drive earlier, more targeted care for those affected by chronic inflammatory pain.

10/31/2025

We’re excited to see RheumNow highlight Dr. Atul Deodhar’s perspective on biomarker discovery in axial spondyloarthritis (axSpA) in their coverage from ACR Convergence 2025 in Chicago.

In this segment, Dr. Deodhar reviews Augurex’s new data presentations (one oral and two posters), which showcased promising data on the Anti-14-3-3eta Multiplex Immunoassay Test improving early detection and aiding in more accurate clinical decision-making in patients with axSpA. In particular, the data highlighted the Anti-14-3-3eta Multiplex Test complementing HLA-B27 and CRP, helping physicians better differentiate axSpA from mechanical back pain to support earlier, more confident diagnosis.

🎥 Watch RheumNow’s full coverage here: https://www.youtube.com/watch?v=X8Sc_3oBSVA

10/28/2025

RheumNow’s on-the-ground coverage at the ACR 2025 conference featured Augurex’s new data on the Anti-14-3-3eta Multiplex Immunoassay Test in axSpA and mechanical back pain patients.

In the segment, Dr. Akhil Sood highlights that “the biomarker can distinguish who has axSpA and who does not, and this is a promising step toward a simple diagnostic tool.”

This recognition underscores the growing clinical relevance of SPINEstat® (Anti-14-3-3eta Multiplex Immunoassay Test) in supporting earlier and more accurate clinical decision-making in axial spondyloarthritis (axSpA).

🎥 Watch the RheumNow coverage here: https://www.youtube.com/watch?v=EvKv45qybDo

10/28/2025

We are pleased to share that the U.S. FDA has granted Breakthrough Device Designation for SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test) - Augurex’s first-in-class blood test to aid in the diagnosis of patients with axial spondyloarthritis (axSpA).

Breakthrough designation recognizes the significant unmet need in early and accurate axSpA diagnosis, where patients often face long delays before receiving appropriate care.

SPINEstat® detects autoantibodies to the 14-3-3eta protein. In combination with clinical findings, signs and symptoms, SPINEstat® may aid in the differentiation of patients with axSpA from those with mechanical back pain, to support earlier, more confident clinical decision making and diagnosis.

🔗 Read the full press release on our website: https://augurex.com/augurex-life-sciences-granted-fda-breakthrough-designation-for-spinestat-its-first-in-class-diagnostic-test-for-axial-spondyloarthritis/

10/22/2025

Patient advocacy is vital in improving awareness, education, and care for those living with rheumatoid arthritis.

We’re proud to partner with AiArthritis as they spotlight the importance of 14-3-3eta testing through their new patient education blog and updated RA diagnosis page, giving patients trusted information that empowers them to play an active role in their care.

This patient-focused resource highlights how the 14-3-3eta blood test can:
✅ Detect RA earlier, even in patients who test negative for RF and anti-CCP
✅ Identify patients at higher risk of joint damage
✅ Track response to treatment and support remission planning

In addition, AiArthritis has updated their RA diagnosis page to include 14-3-3eta, providing patients with even more resources on how this marker can support diagnosis and ongoing care.

👉 Read their blog here: https://www.aiarthritis.org/decoding-biomarkers
👉 Visit the updated RA diagnosis page: https://www.aiarthritis.org/rheumatoidarthritis

10/17/2025

Augurex will exhibit and present new data on the Anti-14-3-3eta Multiplex assay in axial spondyloarthritis (axSpA) at ACR Convergence 2025 in Chicago, Illinois, October 24–29.

Visit us at Booth 919 and join us for our latest research, featuring one oral presentation and two posters that highlight the diagnostic value of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) to enable earlier and more accurate detection of axSpA:

Oral Presentation
- Autoantibodies to 14-3-3eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
📅 Tuesday, Oct 28 | 🕒 3:45–4:00 p.m. CT | Room W183A-C
👨‍⚕️ Presenter: Raj Sengupta

Poster Presentations
- Evaluating the Diagnostic Utility of 14-3-3eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
📅 Sunday, Oct 26 | 🕒 10:30 a.m.–12:30 p.m. CT | Poster Hall F1

- The 14-3-3eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain
📅 Tuesday, Oct 28 | 🕒 10:30 a.m.–12:30 p.m. CT | Poster Hall F1

We look forward to connecting with rheumatology experts, clinicians, and researchers driving innovation in diagnostics to improve patient outcomes. To schedule a meeting during the conference, please reach out to Neil Klompas, Simran Chahal, Anthony Marotta, PhD, or Nima Mazinani, PhD.

🔗 Learn more: https://augurex.com/augurex-to-exhibit-and-present-new-data-on-anti-14-3-3eta-multiplex-in-axial-spondyloarthritis-at-acr-convergence-2025/

Address

887 Great Northern Way, Suite 220
Vancouver, BC
V5T4T5

Telephone

+16046373280

Website

http://www.augurex.com/

Alerts

Be the first to know and let us send you an email when Augurex Life Sciences Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Augurex Life Sciences Corp.:

Shortcuts

Want your practice to be the top-listed Clinic in Vancouver?

Our Story

Augurex is a biotech company that is focused on developing biomarker blood tests that transform patient clinical management for better disease outcomes.

02/03/2026

01/13/2026

12/03/2025

11/25/2025

11/24/2025

11/17/2025

11/02/2025

10/31/2025

10/28/2025

10/28/2025

10/22/2025

10/17/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Our Story